Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.
By Anna R. Giuliano, J. Palefsky, Stephen E Goldstone, Edson D. Moreira, Mary E. Penny, C. Aranda, E. Vardas, Harald Moi, Heiko Jessen, Richard J. Hillman and 10 more. New England Journal of Medicine, 2011
1,202 citations recorded by the source corpus.
Subfields: Epidemiology, Otorhinolaryngology, Surgery
View Paper: https://www.semanticscholar.org/paper/526eb66ddfd49fbe77f5a87e053196f30bf2ba72
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Otorhinolaryngology
Citations in the corpus
- Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels (2013, neutral): “Data from clinical trials have shown that both vaccines prevent vaccine type–related cervical precancers (22,23); the quadrivalent vaccine has been shown to also prevent vaginal, vulvar, and anal precancers (24,25).”
- A review of clinical trials of human papillomavirus prophylactic vaccines. (2012, background): “Efficacy in males The efficacy of Gardasil® was examined in a placebo-controlled, double-blind trial in 4065 men ages 16–26 from 18 countries [51].”